61 results about "Pulmonary Interstitial Fibrosis" patented technology

The invention discloses an application of umbilical cord mesenchymal stem cells in preparation of a pharmaceutical preparation for treating the PF (pulmonary fibrosis). When FN-gamma pretreated mesenchymal stem cells are adopted to treat PF of mice, the survival rate of the mice can be increased obviously, BLM (bleomycin) induced PF pulmonary lesion can be relieved, the pulmonary histopathologic score of the mice can be reduced obviously, and the umbilical cord mesenchymal stem cells have broad application prospect in preparation of medicines for treating the PF.

The invention discloses a cordycepin extract and notoginseng extract and application in prevention and cure pulmonary fibrosis medicine preparation, which is characterized by the following: extracting and condensing from China clothing hairs pore zymocyte powder with water and alcohol; getting cordycepin extract; setting Cordyceps sinensis adenosine, cordycepic acid, and Cordyceps sinensis polysaccharide more than raw bacteria powder about 3-8 double; extracting cordycepin extract from cordycepin crude drug with alcohol; separating large aperture absorption resin; purifying; getting the cordycepin extract; setting the content of cordycepin saponin more than raw cordycepin crude drug for 7-10 double; allocating the cordycepin and cordycepin saponin with mass percent at 90-10% and 10-90%; preparing medicinal compound. This invention possesses very big utility value in clinic.

The invention belongs to the technical field of medicines, and particularly relates to a medicine for treating pulmonary interstitial fibrosis, and a preparation method of the medicine. The medicine for treating pulmonary interstitial fibrosis comprises the following components: astragalus mongholicus, codonopsis pilosula, coastal glehnia root, salvia miltiorrhiza, angelica sinensis, ligusticum wallichii, honeysuckle, fructus forsythiae, scutellaria baicalensis, rhizoma pinelliae preparata, bulbus fritillariae cirrhosae and liquorice. According to the medicine, the astragalus mongholicus and codonopsis pilosula have the effects of tonifying Qi of lung and spleen; the coastal glehnia root has the effect of tonifying Yin of lung and spleen; the salvia miltiorrhiza, angelica sinensis, ligusticum wallichii, honeysuckle, fructus forsythiae, scutellaria baicalensis are used as the supplementary medicines and have the effects of clearing away stasis and resolving phlegm; the rhizoma pinelliae preparata and bulbus fritillariae cirrhosae are respective in moisture state and wet state and are assistant for resolving phlegm; and the liquorice is used for blending other medicines; and all the medicines are blended to realize the effects of supplementing Qi and nourishing Yin, and clearing away stasis and resolving phlegm, and as a result, the Qi can be recovered, the phlegm and stagnant heat can be cleared away, the Qi of the lung and spleen can be tonified by sweat evaporating and turbid descending, the fluid in human body can be smoothly balanced, and the functions can be recovered. The medicine has the functions of supplementing Qi and nourishing Yin, and clearing away stasis and resolving phlegm, and is mainly used for treating breathe hard symptom, weak symptom, dyspnea and tachypnea symptom, coughing symptom and chest pain symptom in clinic.

The invention relates to application of sinomenine as a medicament for preventing and treating pulmonary interstitial fibrosis. The medicament is prepared by sinomenine or pharmaceutically acceptable salt thereof and other adjuvants, wherein sinomenine or pharmaceutically acceptable salt thereof serves as an activating agent. The routes of administration of the medicament include intravenous drip, intramuscular injection, oral administration, transdermal absorption, atomization inhalation and bronchoalveolar lavage. Experiments show that sinomenine does not have obvious difference with the dexamethasone control group in the effect on inhibiting formation of bleomycin-induced pulmonary fibrosis in mice and prove that sinomenine can alleviate pulmonary alveolitis and fibrosis degrees of themice with bleomycin-induced pulmonary fibrosis and the mechanisms are probably realized by inhibiting expressions of TGF (transforming growth factor)-beta1 and alpha-SMA (smooth muscle actin) and thecontent of HYP (hydroxyproline).

The invention relates to a drug, in particular to a Mongolian drug for curing the pulmonary interstitial fibrosis. The Mongolian drug is prepared by the following bulk drugs calculated according to the amounts by weight: 40 to 80 parts of leaf of Chinese ilex, 30 to 50 parts of red sange root, 30 to 50 parts of beach silvertop root, 10 to 30 parts of seabuckthorn fruit, 10 to 30 parts of bitter apricot kernel, 10 to 30 parts of licorice root and 5 to 20 parts of tabasheer. Because the experimental dosage type adopts a capsule, the drug is called compound holly capsule. A plurality of clinical experiments are verified that the compound holly capsule has the functions of clearing Badegan pathogenic heat, reducing phlegm and resolving masses, relieving asthma and activating the channels; the drug has unique therapeutic effect to the interstitial pulmonary fibrosis, and simultaneously has good therapeutic effects on the respiratory diseases, such as the wintercough, the bronchitis, the emphysema and the asthma.

The invention belongs to the traditional Chinese medicine field and relates to the preparation of effective parts of astragalus mongholicus and hedysarum polybotrys and selection thereof for pulmonary fibrosis model intervention so as to obtain further study on the effective parts having the optimal curative effect. An interstitial pulmonary fibrosis model of rats is established through modeling; and compared with the normal rats, the rats having interstitial pulmonary fibrosis have obvious difference and pathologic change typical cases in various related detection indexes and pathologic changes. The various effective parts of astragalus mongholicus and hedysarum polybotrys are capable of suppressing various related indexes of the interstitial pulmonary fibrosis model of rats induced by bleomycin and preventing the development of interstitial pulmonary fibrosis, wherein low and medium dose groups of hedysarum polybotrys flavone have the optimal effect. The degree of the effect of the effective parts of astragalus mongholicus and hedysarum polybotrys on stopping the progress of interstitial pulmonary fibrosis is related to appropriate concentrations of equivalent dugs. Through comprehensive assessment, the hedysarum polybotrys flavone is better in influence on the lung function, HA, LN, HYP and the like of the rats having interstitial pulmonary fibrosis than other effective parts.

The invention discloses a Chinese traditional medicine composition for treating IPF(Idiopathic Pulmonary Fibrosis). The Chinese traditional medicine composition is composed of following ingredients in unit of weight: 10-20 g of radix pseudostellariae, 10-20 g of adenophora tetraphylla, 10-20 g of radix ophiopogonis, 10-20 g of radix scrophulariae, 10-20 g of astragalus membranaceus, 10-20 g of codonopsis pilosula, 10-15 g of rhizoma atractylodis, 10-15 g of rhizoma atractylodis macrocephalae, 10-15 g of the root bark of white mulberry, 10-15 g of scutellaria baicalensis, 10-12 g of peach kernel, 5-10 g of radix platycodi, 10-12 g of fructus aurantii, 10-12 g of radix curcumae, 10-12 g of the root of red-rooted salvia and 5-10 g of radix glycyrrhizae. The Chinese traditional medicine composition provided by the invention has the advantages of simple proportioning and great convenience in use, has the effects of reinforcing Qi and nourishing Yin, promoting blood circulation to remove blood stasis, regulating vital energy and allowing Qi and blood to circulate, and has a remarkable effect on treating IPF.

The invention relates to a Chinese medicinal composition for treating pulmonary interstitial fibrosis, which comprises the following Chinese medicinal components by weight portion: 1 portion of unibract fritillary bulb, 0.1 to 1.0 portion of Paecilomyces bepiali chen, 1.5 to 4 portions of pseudo-ginseng, 1 to 3 portions of Rhodiola rosea L., 1 to 5 portions of Breviscapinun, 1 to 5 portions of red sage root, 1 to 3 portions of ginkgo leaf, 0.1 to 0.6 portion of sanguisuga, 0.1 to 0.6 portion of earthworm and 1 to 5 portions of Common Anemarrhena Rhizome; and the Chinese medicinal components are raw powder of the Chinese medicinal materials or Chinese medicinal extracts equal to crude drug dosages of the Chinese medicinal materials. The Chinese medicinal composition can be used for treating diseases such as pulmonary interstitial fibrosis and the like.

The invention provides a traditional Chinese medicine composition for auxiliary treatment of stage II silicosis. The traditional Chinese medicine composition is prepared from the following traditionalChinese raw materials including herba cordyceps sinensis, unprocessed radix astragali, radix codonopsis, stir-fried bighead atractylodes rhizome, poria cocos, rhizoma pinelliae preparata, dried orange peel and radix glycyrrhizae preparata. The traditional Chinese medicine preparation has the good effects on the auxiliary treatment of silicosis, particularly the stage II silicosis. The traditionalChinese medicine composition is used for treating silicosis by assisting medicine for inhibiting fibroplasia; the effects of clearing away the liver-fire and eliminating stagnation can be achieved; the degradation of the pulmonary interstitial fibrosis is promoted; the clinic symptoms can be effectively reduced; the disease condition development is effectively reduced.

The invention provides an application of notoginseng saponins Rg 1 in preparing medicine for treating pulmonary interstitial fibrosis. Pharmacological experiments show that if in vitro, the notoginseng saponins Rg 1 can inhibit the activity of human embryonic lung fibroblast and has good dose-dependent; if in vivo, the notoginseng saponins Rg 1 can decrease the lung coefficientand the lung hydroxyproline content of a mouse with pulmonary interstitial fibrosis; the notoginseng saponins Rg 1 can also reduce the pulmonary alveolitis and the degree of pulmonary interstitial fibrosis of the mouse with pulmonary interstitial fibrosis; the raw materials of the notoginseng saponins Rg 1 are easy to obtain, and can be prepared into various common dosage forms such as tablets, capsules, and injections; and the preparation method is simple.

The invention relates to a traditional Chinese medicine granule for treating diffuse interstitial pulmonary fibrosis lung and kidney qi insufficiency syndrome, and can effectively solve the problem of medication in later period treatment of the diffuse interstitial pulmonary fibrosis. In order to solve the problems, the traditional Chinese medicine granule has the technical scheme that ginseng is crushed to obtain ultrafine ginseng powder A; dried orange peel is subjected to water vapor distillation volatile oil extraction; beta-cyclodextrin inclusion compounds B are prepared; the dried orange peel medicine dregs, thunberg fritillary bulb, cortex moutan, epimedium and ginkgo biloba are merged; the mixture is subjected to reflux extraction by 70-percent ethanol to obtain first extract paste; the mixed medicine dregs of the dried orange peel, the thunberg fritillary bulb, the cortex moutan, the epimedium and the ginkgo are decorated and boiled by water to obtain first filter liquid; dwarf lilyturf roots, prepared rehmannia roots, trichosanthes kirilowii Maxim, Chinese pulsatilla roots and coix seeds are decorated and boiled by water to obtain second filter liquid; the first filter liquid and the second filter liquid are merged to obtain second extract paste; the first extract paste and the second extract paste are merged to prepare extract paste fine powder C; ginseng ultrafine powder A, the beta-cyclodextrin inclusion compounds B and the extract paste fine powder C are merged; uniform mixing, pelletization and drying are performed; the traditional Chinese medicine granule is obtained. The traditional Chinese medicine granule has the advantages that the matching is reasonable; the method is scientific; the curative effect is exact and economic; the social benefits are obvious.

The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.

The invention relates to application of a polypeptide compound, the polypeptide compound has the characteristics of high enzymolysis stability, high biological activity, no adverse reaction and the like, and the polypeptide compound can improve and treat non-alcoholic liver diseases including fatty liver, cholestatic liver cirrhosis, inflammation, liver injury and fibrosis. And meanwhile, lung diseases accompanied by fibrosis symptoms, such as idiopathic pulmonary interstitial fibrosis, can be improved and treatment.

The invention provides a phlegm reducing traditional Chinese medicine composition. The phlegm reducing traditional medicine composition is prepared from the following raw materials, in parts by weight: 2-12 parts of cortex mori, 1-3 parts of semen brassicae, 1-3 parts of fructus schisandrae, 2-12 parts of fructus perillae, 2-12 parts of semen lepidii, 1-3 parts of rhizoma pinelliae, 2-12 parts ofradix asteris, 1-3 parts of exocarpium citri rubrum and 1-3 parts of radix platycodi. The phlegm reducing traditional Chinese medicine composition achieves the efficacy of phlegm reducing and promoting, reliefs the symptoms of abundant expectoration, coughing, asthma and dyspnea caused by acute and chronic respiratory diseases, further rectifies the phlegm-damp habitus of chronic respiratory diseases, interdicts or delays disease development, and thus achieves the purpose of clinical rehabilitation. The phlegm reducing traditional Chinese medicine composition can be used for treating the diseases such as chronic pharyngitis, chronic bronchitis, bronchial asthma, chronic obstructive pulmonary disease, interstitial pneumonia and pulmonary interstitial fibrosis, has an outstanding curative effect, does not contain chemical synthesis matter, and is suitable for a wide range of groups.

The invention belongs to the technical field of traditional Chinese medicines and in particular relates to traditional Chinese medicine tablets for treating pulmonary interstitial fibrosis and a preparation method thereof. The traditional Chinese medicine tablets are prepared from the following traditional Chinese medicines in parts by weight: 15-20 parts of liquorice, 6-8 parts of rhizoma zingiberis, 10-15 parts of the tuber of stemona, 8-10 parts of semen coicis, 10-15 parts of lily, 6-8 parts of radix ophiopogonis, 15-20 parts of the root bark of white mulberry, 8-10 parts of poria cocos, 15-20 parts of the root of straight ladybell, 10-15 parts of astragalus, 6-8 parts of cortex lycii radicis, 15-20 parts of stephania terandra, 4-6 parts of semen lepidii, 10-15 parts of sticky rice, 8-10 parts of peach kernel, 8-10 parts of polished round-grained rice, 15-20 parts of indigo naturalis, 6-8 parts of clam meal, 4-6 parts of the bulb of fritillary and 15-20 parts of rehmannia glutinosa. The traditional Chinese medicine tablets purely belong to traditional Chinese medicine preparations, the autoimmune activity of lung cells is activated by virtue of herbal treatment, the effects of controlling fibrosis and restoring the respiratory function are achieved, and the preparation method is simple and feasible and easy to popularize and use.

The invention belongs to the technical field of traditional Chinese medicines and in particular relates to a traditional Chinese medicine formula for treating pulmonary interstitial fibrosis. The traditional Chinese medicine formula is prepared from the following traditional Chinese medicine raw materials in parts by weight: 15-20 parts of cordyceps sinensis, 10-15 parts of lucid ganoderma, 10-15 parts of astragali radix, 5-10 parts of radix asteris, 3-5 parts of bulbus fritillariae cirrhosae, 3-5 parts of cinnamon, 3-5 parts of poria cocos, 3-5 parts of rhizoma polygonati, 5-8 parts of the fruit of Chinese wolfberry and 5-8 parts of liquorice. According to the conditioning effects of the traditional Chinese medicines, the autoimmune activity of lung cells is activated, the effects of controlling fibrosis and restoring respiratory functions are achieved, and the preparation method is simple, feasible and easy to implement.

The invention relates to health food for relieving pulmonary fibrosis. The health food for relieving pulmonary fibrosis is prepared with fig, radix angelicae sinensis, earthworm, rhizoma chuanxiong, radix astragali, stem of noble dendrobium, borneol, and common food accessories. The health food for relieving pulmonary fibrosis has the effect of slowing pulmonary interstitial fibrosis of experimental rats.

The invention relates to a traditional Chinese medicine composition for treating pulmonary interstitial fibrosis, a traditional Chinese medicine decoction-free granule and application, and belongs tothe technical field of traditional Chinese medicine. The traditional Chinese medicine composition is prepared from, by weight, 9-30 parts of crude radix astragali, 9-15 parts of radix codonopsis, 6-12parts of radix ophiopogonis, 10-15 parts of wax gourd kernels, 10-15 parts of rhizoma phragmitis, 9-30 parts of crude coix seeds, 5-10 parts of peach kernels, 6-15 parts of honeysuckle flowers, 6-15parts of radix angelicae sinensis and 2-6 parts of crude licorice roots. The traditional Chinese medicine decoction-free granule is prepared from the above-mentioned traditional Chinese medicine formula granules by weight. The invention discloses application of the traditional Chinese medicine composition and traditional Chinese medicine decoction-free granule in preparing medicine for treating the pulmonary interstitial fibrosis. The traditional Chinese medicine composition and the traditional Chinese medicine decoction-free granule have the advantages of benefiting qi, nourishing yin, eliminating phlegm and removing blood stasis, have the anti-inflammatory, anti-oxidation, anti-angiogenesis, anticoagulation, antithrombotic and anti-platelet agglutination functions, and have the functionof regulating the immune function of the body.

The invention provides a composite of breviscapinum and panax notoginseng saponins Rg1 for treating pulmonary fibrosis, wherein the weight ratio of the breviscapinum to the panax notoginseng saponins Rg1 is 2-5:1-2. The invention also provides application of the composite in the preparation of a medicament for treating the pulmonary fibrosis. The composite of the breviscapinum and the panax notoginseng saponins Rg1 is formulated in a certain proportion and has the advantages of favorable pulmonary fibrosis resistance, remarkable effect and little side effects. Raw materials of the composite are easily obtained and can be prepared in various common dosage forms, such as tablets, capsules, injections and the like, through a conventional method with simple preparation method. The pharmacological action of the composite is obvious; in vitro, the composite can inhibit the activity of human embryonic lung fibroblasts and has favorable dosage dependence; and in vivo, the composite can lower the lung coefficient of a mouse with the pulmonary fibrosis and the content of hydroxyproline of lung tissues and also relieve the alveolitis of the mouse with the pulmonary fibrosis and reduce the degree of the pulmonary fibrosis.

The invention discloses a pharmaceutical composition for idiopathic pulmonary fibrosis and application thereof. The pharmaceutical composition for the idiopathic pulmonary fibrosis comprises pirfenidone and dextromethorphan. The content of the pirfenidone is 200 to 600 mg, and the content of the dextromethorphan is 7.5 mg. The pharmaceutical composition for resisting the idiopathic pulmonary fibrosis is an oral medicine. An administration mode of the pharmaceutical composition for resisting the idiopathic pulmonary fibrosis is that the single dose of the pirfenidone is 200-600 mg, and the pirfenidone is taken for three times a day; and the single dose of the dextromethorphan is 7.5 mg, and the dextromethorphan is taken once a day. According to the administration dosage of the pirfenidone, the single dose of the pirfenidone is increased by 200-400 mg per week. The dosage of the pirfenidone is increased to 400-600 mg each time within two weeks. According to the invention, acute exacerbation of pulmonary fibrosis can be slowed down, pulmonary interstitial fibrosis is relieved compared with the previous condition, and the life quality is improved.

The invention belongs to the technical field of traditional Chinese medicine and particularly relates to a traditional Chinese medicine prescription for treating the pulmonary interstitial fibrosis. The traditional Chinese medicine is prepared from the following traditional Chinese medicine raw materials in parts by weight: 15-20 parts of cordyceps sinensis, 5-10 parts of rhodiola rosea, 5-10 parts of gynostemma pentaphylla, 3-5 parts of wahlenbergia marginata, 3-5 parts of peperomia blanda, 3-8 parts of greenish lily flower, 3-8 parts of ophiopogon root, 3-5 parts of rhizoma panacis majoris, 3-8 parts of radix asteris, 3-5 parts of fritillaria cirrhosa, 3-5 parts of radices primulae, 3-5 parts of walking spleenwort, 1-3 parts of toasted ephedra, 3-5 parts of patrinia, 1-3 parts of dysosma versipellis, 1-3 parts of chrysanthemum morofolium ramat, 3-5 parts of folium agaves america nae, 3-5 parts of erigeron breviscapus, 3-5 parts of rabdosia japonica, 1-3 parts of livistona chinensis, and 1-3 parts of stigma croci. By virtue of the conditioning of the traditional Chinese medicines, the autoimmune activity of the lung cell can be activated, the fibrosis can be controlled and the respiratory function can be recovered; the preparation method is simple and convenient and easy to implement.

The invention discloses a Chinese medicine formulation for curing pulmonary fibrosis. it is prepared from, by weight, 10 g codonopsis pilosula, 10 g wolfiporia cocos, 20 g atractylodes macrocephala, 15 g astragalus mongholicus, 10 g angelica sinensis, 10 g fritillaria thunbergii, 6 g sophoraflavescens, 3 g panax notoginseng powder, 13 g earthworm, 10 g turtle shell (decocted earlier), 15 g cornus officinalis, 30 g china dodder, 10 g acorus tatarinowii, 10 g radix curcumae. The preparation and using methods of the Chinese medicine composition of the invention are: decocting in water for an oral dose, one dose a day, taking twice a day separately, seven days as a course of treatment, generally taking 1-2 courses.

An application of the scabrous elephantfoot herb in treating the hepatofibrosis of SARS patient is disclosed.

The present invention discloses one kind of liposome aerosol with protease inhibitor for preventing and treating alveolitis and pulmonary interstitial fibrosis. The liposome aerosol of the present invention is prepared with protease inhibitor, lecithin, cholesterol, vitamin E, ether and other ingredients, and through rotary evaporation, ultrasonic crushing, vibrating stirring, compression atomizing and other steps.

The invention discloses a traditional Chinese medicine composition for treating idiopathic pulmonary fibrosis (IPF). The composition comprises the following components by weight: 10-20g of Chinese dates, 10-20g of American ginseng, 10-20g of radix rehmanniae, 10-20g of red peony root, 10-20g of radix astragali, 10-20g of radix codonopsis, 10-15g of Chinese wolfberry root-bark, 10-15g of radix asparagi, 10-15g of white mulberry root-bark, 10-15g of wild chrysanthemum, 10-12g of cape jasmine fruit, 5-10g of barbated skullcup herb, 10-12g of reed rhizome, 10-12g of folium mori, 10-12g of salvia miltiorrhiza and 5-10g of licorice roots northwest origin. The composition is simple in proportioning, is convenient to use, has the functions of tonifying qi and yin, promoting blood circulation to remove blood stasis, activating qi by opening chests and promoting qi and blood circulation, and has obvious IPF treatment effects.

The invention relates to a digitalized detecting analysis method for pulmonary interstitial fibrosis based on a lung sound. According to the method, first, normalization processing is conducted on lung sound data acquired in a certain time period, then wavelet decomposition is conducted, a wavelet decomposition detail component in a main distribution frequency band of a pulmonary interstitial fibrosis crackle signal is selected, and standard deviation of a related wavelet component decomposition signal is calculated. Quantitative analysis is conducted on the lung sound of a patient with the pulmonary interstitial fibrosis by the adoption of the detecting method to evaluate the severe degree of the pulmonary interstitial fibrosis of the patient, health of the patient is not influenced, detection is safer, detection and analysis can be conducted for many times, analysis is more objective, accuracy is high, cost is low, operation is simple, and the digitalized detecting analysis method is suitable for monitoring the illness degree of a patient with interstitial pneumonia.